NICE draft say No to BMS and Novartis's leukaemia treatments
This article was originally published in Scrip
NICE, the health technology appraisal institute for England and Wales, has initially rejected both Bristol-Myers Squibb's Sprycel (dasatinib) and Novartis's Tasigna (nilotinib) for some NHS patients with chronic myeloid leukaemia (CML). The institute said weak data cast doubt over the drugs' effectiveness.
You may also be interested in...
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
Patient access schemes have helped the Scottish Medicines Consortium recommend rare disease products, including Regeneron/Sanofi’s Libtayo for skin cancer.